Commission Implementing Regulation (EU) 2023/1757 of 11 September 2023 amending Implementing Regulation (EU) No 540/2011 as regards the extension of the approval periods of the active substances bensulfuron, chlormequat, chlorotoluron, clomazone, daminozide, deltamethrin, eugenol, fludioxonil, flufenacet, flumetralin, fosthiazate, geraniol, MCPA, MCPB, propaquizafop, prosulfocarb, quizalofop-P-ethyl, quizalofop-P-tefuryl, sodium 5-nitroguaiacolate, sodium o-nitrophenolate, sodium p-nitrophenolate, sulfuryl fluoride, tebufenpyrad, thymol, and tritosulfuron (Text with EEA relevance)

• CELEX: Implementing Regulation (EU) 2023/1757
• Articles: 3

Article 1

The Annex to Implementing Regulation (EU) No 540/2011 is amended in accordance with the Annex to this Regulation.

Article 2

This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union .

Schedules & Appendices

ANNEX

ANNEX

The Annex to Implementing Regulation (EU) No 540/2011 is amended as follows:

1.

Part A is amended as follows:

(1)

in the sixth column, expiration of approval, of row 40, Deltamethrin, the date is replaced by ‘15 August 2026’;

(2)

in the sixth column, expiration of approval, of row 65, Flufenacet, the date is replaced by ‘15 June 2025’;

(3)

in the sixth column, expiration of approval, of row 69, Fosthiazate, the date is replaced by ‘31 January 2027’;

(4)

in the sixth column, expiration of approval, of row 102, Chlorotoluron, the date is replaced by ‘15 August 2026’;

(5)

in the sixth column, expiration of approval, of row 104, Daminozide, the date is replaced by ‘15 September 2025’;

(6)

in the sixth column, expiration of approval, of row 107, MCPA, the date is replaced by ‘15 August 2026’;

(7)

in the sixth column, expiration of approval, of row 108, MCPB, the date is replaced by ‘15 August 2026’;

(8)

in the sixth column, expiration of approval, of row 160, Prosulfocarb, the date is replaced by ‘31 January 2027’;

(9)

in the sixth column, expiration of approval, of row 161, Fludioxonil, the date is replaced by ‘15 June 2025’;

(10)

in the sixth column, expiration of approval, of row 162, Clomazone, the date is replaced by ‘15 June 2025’;

(11)

in the sixth column, expiration of approval, of row 186, Tritosulfuron, the date is replaced by ‘15 July 2025’;

(12)

in the sixth column, expiration of approval, of row 271, Bensulfuron, the date is replaced by ‘15 August 2026’;

(13)

in the sixth column, expiration of approval, of row 272, Sodium 5-nitroguaiacolate, the date is replaced by ‘31 January 2027’;

(14)

in the sixth column, expiration of approval, of row 273, Sodium o-nitrophenolate, the date is replaced by ‘31 January 2027’;

(15)

in the sixth column, expiration of approval, of row 274, Sodium p-nitrophenolate, the date is replaced by ‘31 January 2027’;

(16)

in the sixth column, expiration of approval, of row 275, Tebufenpyrad, the date is replaced by ‘31 January 2027’;

(17)

in the sixth column, expiration of approval, of row 276, Chlormequat, the date is replaced by ‘28 February 2027’;

(18)

in the sixth column, expiration of approval, of row 278, Propaquizafop, the date is replaced by ‘28 February 2027’;

(19)

in the sixth column, expiration of approval, of row 279, Quizalofop-P-ethyl and Quizalofop-P-tefuryl, the date is replaced by ‘28 February 2027’;

(20)

in the sixth column, expiration of approval, of row 307, Sulfuryl fluoride, the date is replaced by ‘31 January 2027’.

2.

Part B is amended as follows:

(1)

in the sixth column, expiration of approval, of row 45, Eugenol, the date is replaced by ‘30 April 2026’;

(2)

in the sixth column, expiration of approval, of row 46, Geraniol, the date is replaced by ‘30 April 2026’;

(3)

in the sixth column, expiration of approval, of row 47, Thymol, the date is replaced by ‘30 April 2026’;

3.

Part E is amended as follows:

in the sixth column, expiration of approval, of row 1, Flumetralin, the date is replaced by ‘

11 May 2026

’.